Up next

Autoplay

Tissue biomarkers for response to anti-TNF therapy with Tom Thomas.

0 Views • 08/19/25
Share
Side Effects
Side Effects
Subscribers
0

Tissue biomarkers for response to anti-TNF therapy across rheumatoid arthritis and inflammatory bowel disease (the TAURUS study)

Anti-TNF therapy is the most commonly used first line biologic medication in inflammatory bowel disease. For every 10 patients that take an anti-TNF medication, only around 6-7 patients benefit from it. At the moment we don’t know why this medication works in some patients but not in others. Advances in technology allow us to look at the role of individual cells in disease in greater detail than ever before. The TAURUS study aims to sample tissue from the bowel in patients receiving adalimumab (also known as Humira) before and after treatment. By doing this we will be able to look at the changes made by this treatment at the most fundamental level. To find out what impact adalimumab has on IBD symptoms and the quality of life of patients, we have also incorporated Truecolours, an online symptom tracking system into the study. By comparing changes to the bowel tissue before and after treatment, we aim to understand the biological pathways that are involved in persistent disease, which can help target new drug treatments. We also plan to look at whether there are clues in the bowel tissue prior to treatment that could tell us whether anti-TNF therapy would be of benefit in certain patients compared to others.


To find out more visit ► http://crohnsandcolitis.org.uk

Show more
0 Comments sort Sort By

Up next

Autoplay